Predictmedix to deploy its coronavirus (COVID-19) screening technology, along with its alcohol and impairment screening technology for Indian Oil Corporation

Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) has announced that it will be deploying its coronavirus (COVID-19) screening technology, along with its alcohol and impairment screening technology for Indian Oil Corporation Ltd (NSE:IOC.NS) at Indian Oil Bhawan in New Delhi, and also revealed a new advisory board appointment and patent filing. The group said it is expected that the two Predictmedix technologies will begin to be deployed by the FORTUNE 500 Indian company within the next 3-4 weeks. READ: Predictmedix poised to take technology to the UK as it wins sales contract with NHS supplier The COVID-19 screening technology is designed to mass screen for symptomatic individuals to help reduce the risk of transmission in places which have a large movement of people. At the same time, impairment remains to be a massive health and safety issue at the workplace and Predictmedix impairment detection technology is designed to identify alcohol and cannabis impairment. In a statement, Dr Kushwah, COO of Predictmedix commented: "The deployment of our COVID-19 screening and impairment technology at IOCL which is a Fortune 500 company marks our entry into the Oil & Gas sector which is one of the largest industrial sectors and it further highlights the market need for the suite of technologies developed by Predictmedix". Indian Oil Corporation Limited (IOCL), commonly known as Indian Oil is an Indian government-owned oil and gas company headquartered in New Delhi. It is ranked 1st in Fortune India 500 list for year 2016 and 117th in Fortune Global 500 list of world's largest companies in the year 2019. It is India's largest downstream oil company, with a workforce of more than 33,000 employees, with 2019 revenue of US$85 billion. Board appointment, patent award Predictmedix also announced the appointment of Kiran Kumari to the advisory board to assist with business development in Asia Pacific. Kiran is a senior Oil and gas executive and has assisted some of the largest multinational conglomerates with business development in Asia. The company revealed as well that it filed a patent application - 63058567: Utilizing healthcare providers network effect to increase compliance for better health outcomes - with the United States Patent and Trademark Office (USPTO) on July 30, 2020. The patent further enhances the features offered by Predictmedix telehealth/telemedicine and remote patient monitoring platform. The present invention provides a novel method and system of management of rewards for care provider network for assisting in improved health of the patient and for compliance to a treatment protocol. The patent covers a partner reward management system and method for care partners/care providers to collectively contribute to improved health of the patient and accordingly rewarding the care providers and other wellness partners. Disruptive tools for impairment testing and healthcare Predictmedix is an artificial intelligence (AI) company developing disruptive tools for impairment testing and healthcare. It is intended that the company's cannabis and alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses facial and voice recognition to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any bodily fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice. The company is also developing AI-based screening for the healthcare industry and is expanding its proprietary technology to screen for infectious diseases such as influenza and coronaviruses (COVID-19). The technology is for mass screening and is to be used to predict and identify individuals who have the highest likelihood of being infected with COVID-19. Predictmedix is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer's disease. Contact the author at jon.hopkins@proactiveinvestors.com